Publications by authors named "Lascoux-Combe C"
Article Synopsis
- Surveillance of Transmitted Drug Resistance (TDR) is essential for understanding the changes in HIV trends, with a focus on multiple types of antiretroviral drugs and new treatments.
- A study involving 85 individuals diagnosed with primary HIV-1 infection (PHI) from 2020 to 2023 analyzed genetic sequences to identify TDR and its impact on drug resistance, revealing varying levels of resistance to several drug classes.
- The findings highlight the importance of monitoring TDR at the onset of HIV infection to improve treatment strategies and the effectiveness of pre-exposure prophylaxis (PrEP) with newer drug options.
Background & Aims: In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate the efficacy and safety of BLV in patients with HIV and HDV coinfection.
Methods: Patients received BLV 2 mg ± pegylated interferon-α (pegIFNα) according to the physician's decision.
Article Synopsis
- The study evaluates a new ultrasensitive test for Hepatitis B, called HBsAg Next (HBsAgNx), which is significantly more sensitive than current tests, making it crucial for accurate diagnosis and monitoring.
- Researchers analyzed 253 samples and found that HBsAgNx had a strong agreement with traditional testing methods while detecting cases that were missed by the older assays, including instances of occult HBV infection.
- The findings suggest that HBsAgNx offers better sensitivity and specificity, which may improve clinical outcomes by enabling earlier detection of infections and monitoring of reactivations in patients.
Article Synopsis
- * Researchers found low levels of cabotegravir in patients after 1 and 3 months, particularly in those who didn't have an oral lead-in before the injection.
- * Additionally, higher body mass index (BMI) was linked to reduced cabotegravir concentrations, indicating that these factors can affect treatment efficacy.
Article Synopsis
- * Results showed that 61.7% of the participants acquired HIV after arriving in France, with 13.1% of those cases occurring within the first year of migration.
- * Factors such as older age at migration, region of origin, social disadvantage, and the number of sexual partners were linked to a higher likelihood of acquiring HIV within the first year.
Objectives: To determine the extent of hepatitis B virus (HBV) suppression and its association with seroclearance of hepatitis 'e' antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HIV/HBV-coinfected patients undergoing long-term tenofovir-based antiretroviral therapy (ART).
Methods: We prospectively followed 165 HIV/HBV-coinfected patients undergoing tenofovir-based ART. Serum HBV-DNA viral loads and HBeAg and HBsAg status were obtained at tenofovir initiation and every 6-12 months.
Background & Aims: Data on liver fibrosis evolution and its involvement in liver-related morbidity are scarce in individuals with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infection during treatment. We identified profiles of liver fibrosis evolution in coinfected patients undergoing tenofovir (TDF).
Methods: We included 169 HIV-HBV-coinfected patients on TDF-based antiretroviral therapy.
Background: In individuals living with human immunodeficiency virus (HIV) and hepatitis B virus (HBV), widespread tenofovir (TDF)-containing antiretroviral therapy (ART) has led to substantial decreases in HBV-DNA and HIV-RNA detection. However, the links between viral replication, liver fibrosis, and mortality remain unclear.
Methods: A total of 300 individuals living with HIV-HBV and undergoing ART were prospectively followed.
Article Synopsis
- The study compared how quickly and effectively men starting a dolutegravir-based HIV treatment reached undetectable levels of the virus in seminal plasma versus blood plasma.
- At the beginning, viral loads were higher in blood plasma compared to seminal plasma.
- By week 48, a higher percentage of participants achieved undetectable viral load in seminal plasma (93%) compared to blood plasma (84%), with quicker undetectable levels in seminal plasma (8 weeks) than in blood plasma (24 weeks).
Background: Previous large-scale studies have examined the effect of chronic hepatitis B virus (HBV) infection on overall and cause-specific mortality in individuals with HIV. However, few studies have collected data on the subclinical indicators of HBV that lead to these severe outcomes in the coinfected population.
Objective: In this study, we aim to describe the procedures of a cohort study extension aimed at assessing HBV-DNA replication, serological markers of HBV (hepatitis B e antigen [HBeAg] and hepatitis B surface antigen), and liver fibrosis and how these subclinical outcomes relate to mortality in predominately tenofovir-treated, coinfected patients with HIV-HBV.
Background: Quantitative hepatitis B core-related antigen (qHBcrAg) or antihepatitis B core antibody (qAnti-HBc) could be useful in monitoring liver fibrosis evolution during chronic hepatitis B virus (HBV) infection, yet it has not been assessed in human immunodeficiency virus (HIV)-HBV-coinfected patients undergoing treatment with tenofovir (TDF).
Methods: One hundred fifty-four HIV-HBV-infected patients initiating a TDF-containing antiretroviral regimen were prospectively followed. The qHBcrAg and qAnti-HBc and liver fibrosis assessment were collected every 6-12 months during TDF.
Objective: To assess whether quantified hepatitis B core-related antigen (qHBcrAg) is a surrogate marker of intrahepatic replication in HIV and hepatitis B virus (HBV) coinfection.
Design: Cross-sectional study of 31 HIV-HBV-infected patients (total liver biopsies, n = 38) from a well defined cohort.
Methods: Spearman's rank correlation coefficients were calculated between qHBcrAg and intrahepatic markers of HBV replication [total intrahepatic-DNA, covalently closed circular (ccc) DNA, cccDNA : total intrahepatic-DNA ratio].
Background: An increased risk of cardiovascular disease (CVD) was reported in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), without identifying factors associated with atherosclerotic CVD (ASCVD) events.
Methods: HIV-HCV coinfected patients were enrolled in the Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS) CO13 HEPAVIH nationwide cohort. Primary outcome was total ASCVD events.
Article Synopsis
- The study used next-generation sequencing to analyze HIV envelope gene diversity and quantity in different body fluids of eight patients with acute HIV infection.
- The findings revealed that the levels of HIV RNA were highest in plasma, followed by seminal fluid and saliva, with very low genetic diversity observed within the viral populations.
- Researchers noted that most patients had a single dominant viral haplotype across compartments, indicating low diversity in early infection stages, which could inform patient-specific therapeutic approaches.
Background: The aim of the current study was to describe the kinetics of quantified hepatitis B core-related antigen (qHBcrAg) and quantified anti-hepatitis B core antibody (qAnti-HBc) during tenofovir (TDF) treatment and assess their ability to predict hepatitis B e antigen (HBeAg) seroclearance in patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus.
Methods: Serum qHBcrAg, qAnti-HBc, and hepatitis B virus DNA were obtained at TDF initiation and every 6-12 months. The on-treatment kinetics of qHBcrAg (ΔqHBcrAg) and qAnti-HBc (ΔqAnti-HBc) were estimated using mixed-effect linear regression.
Design: Current international guidelines recommend either boosted protease inhibitor (PI/r)-based or integrase inhibitors (INSTI)-based regimens during primary HIV infection (PHI), even though the latter have only demonstrated their superiority at the chronic stage. We compared the effectiveness of INSTI-based versus PI/r-based combined antiretroviral therapy (cART) initiated during PHI.
Methods: This study was conducted among patients who initiated cART between 2013 and 2017, using data from the ANRS-PRIMO cohort and the Dat'AIDS study.
Objectives: HIV/hepatitis C virus (HCV) co-infection leads to major complications, and noninvasive markers developed to stage liver fibrosis could be used as prognostic markers. We aimed to compare the performances of liver stiffness (LS), fibrosis-4 (FIB-4), and aspartate aminotransferase to platelet ratio index (APRI) to predict liver-related events in HIV/HCV co-infected patients.
Patients And Methods: HIV/HCV co-infected patients from the ANRS CO13 HEPAVIH cohort were included if they had LS, FIB-4, and APRI measurements done in a window of 3 months.
Background: The association between liver stiffness measurements (LSM) and mortality has not been fully described. In particular the effect of LSM on all-cause mortality taking sustained virological response (SVR) into account needs further study.
Methods: HIV/HCV participants in the French nation-wide, prospective, multicenter ANRS CO13 HEPAVIH cohort, with ≥1 LSM by FibroScan (FS) and a detectable HCV RNA when the first valid FS was performed were included.
Background: Hepatitis C virus (HCV) and HIV infections are associated with higher risk of autoimmune diseases and T-cell dysfunction.
Setting: We evaluate prevalence and factors associated with the presence of autoimmune antinuclear (ANA), anti-smooth muscle actin (aSMA), and anti-liver kidney microsome (aLKM1) antibodies (Ab) in HCV/HIV-coinfected patients during the post-combined antiretroviral therapy era.
Methods: A cross-sectional observational study nested in the ANRS CO13 HEPAVIH cohort (NCT number: NCT03324633).
Compared to the general population, HIV-infected patients are at higher risk of developing non-AIDS-defining cancers. Chronic HCV infection has also been associated with a higher risk than that of the general population of developing cancers other than hepatocarcinoma. Evaluation of the impact of HCV-related factors on non-AIDS-defining and non HCV-liver (NANL) related cancers among HIV/HCV co-infected patients are scarce.
View Article and Find Full Text PDFIntroduction: Infection with hepatitis B virus (HBV) genotype G has been associated with increased liver fibrosis levels compared with other genotypes in cross-sectional studies, yet its role in fibrosis evolution remains to be established.
Methods: In this prospective cohort study, 158 human immunodeficiency virus (HIV)-HBV coinfected patients had available HBV genotyping at baseline. Liver fibrosis was assessed at baseline and every 6 to 12 months by the FibroTest (BioPredictive, Paris, France).
The precore (pc) W28* mutation arises from immune-selective pressures during the hepatitis B "e" antigen (HBeAg)-positive phase of chronic hepatitis B virus (HBV) infection and has been linked to severe liver-related morbidity. Here, we examined the determinants of harboring this mutation and its rate of emergence in treated patients co-infected with human immunodeficiency virus (HIV) and HBV. In a three-year prospective cohort of 165 HIV-HBV co-infected patients, pcW28* mutation was determined via DNA-chip during yearly sampling.
View Article and Find Full Text PDF